The site has a new purpose-built, 100-bed facility designed to run clinical pharmacology studies in healthy, diabetic and obese participants. Well-known for conducting first-in-human, proof-of-concept studies and participating as a multicenter site in diabetes and obesity trials, the new facility consolidates its operations into one four-story building.
In addition to a large database of normal healthy participants, Type I and Type II diabetics and obese patients, Cetero also has access to patients with hypogonadism, neuropathy, osteoporosis and erectile dysfunction.
Sherwyn Schwartz, CEO of San Antonio facility at Cetero, said: “We are excited that this new building further expands our capabilities and capacity for clinical research. One notable expansion is increased capacity to perform euglycemic and insulin-clamp studies. These specialized studies are ideal for establishing proof-of-concept for novel compounds, or even comparing compounds to show superiority or equivalence.”